Sengenics is a Functional Proteomics company focused on leveraging its core patented KREX» technology for developing new diagnostic tests and therapies for Human disease. The fundamental research for KREX» was led by Professor Jonathan Blackburn as a collaboration between Oxford and Cambridge University in the late 1990s. The uniqueness of the KREX» technology stems from the fact that every protein is correctly folded and functional. Every protein on the array is cloned in frame with the BCCP folding marker. Misfolded proteins will not become biotinylated and are washed away. Only correctly folded proteins are biotinylated and immobilised on the array. Key applications of the KREX» technology are autoantibody biomarker discovery, cancer immunotherapy, predicting vaccine responsiveness and infectious diseases diagnostics. Sengenics has commercial operations with state-of-the-art proteomics laboratory and production facilities in Singapore, the UK and South Africa. Sengenics has forged mutually beneficial strategic corporate and academic collaborations with some of the worldÍs top pharmaceutical companies, world-class universities and leading research institutions by offering solutions in three categories: Standard array format, custom array format and the Immunome Technology Access Program (iTAP). The company has 15 granted patents in the USA, UK, EU, Japan, Canada and Australia. Sengenics also has IP positions on diagnostics, therapeutics and screening of eleven Human diseases ranging from Cancers, Autoimmune disorders, Vaccines, Cancer Immunotherapy and Transplantation rejection screening.